The study is designed to evaluate efficacy of PH-10 in a total of 20 subjects with mild to severe forms of the disease. In the study, subjects will apply PH-10 daily for up to four weeks to their skin areas affected by atopic dermatitis. Response will be observed weekly throughout this treatment phase, and for one month after the end of this period.
Response will be graded using the Investigator’s Global Assessment (IGA) and Eczema Area Severity Index (EASI) assessment of response. Changes in pruritus (itching) will also be assessed, along with comprehensive safety monitoring. The study will be conducted at the International Dermatology Research of Miami, Florida.
Craig Dees, CEO of Provectus, said: “This study will allow us to assess both safety and efficacy of PH-10 for atopic dermatitis. The daily application of PH-10 in this study will also provide information relevant for treatment of other dermatologic conditions, such as psoriasis and infectious diseases of the skin, including antibiotic resistant Staphylococcus aureus (MRSA), which is a growing public health concern.”